Ignacio Gil‐Bazo

5.1k total citations
103 papers, 2.6k citations indexed

About

Ignacio Gil‐Bazo is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Ignacio Gil‐Bazo has authored 103 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 58 papers in Pulmonary and Respiratory Medicine, 54 papers in Oncology and 36 papers in Molecular Biology. Recurrent topics in Ignacio Gil‐Bazo's work include Lung Cancer Treatments and Mutations (35 papers), Colorectal Cancer Treatments and Studies (13 papers) and Lung Cancer Research Studies (13 papers). Ignacio Gil‐Bazo is often cited by papers focused on Lung Cancer Treatments and Mutations (35 papers), Colorectal Cancer Treatments and Studies (13 papers) and Lung Cancer Research Studies (13 papers). Ignacio Gil‐Bazo collaborates with scholars based in Spain, Belgium and United States. Ignacio Gil‐Bazo's co-authors include Christian Rolfo, Inés López, Iosune Baraibar, Patrick Pauwels, Marco Giallombardo, Luis E. Raez, Marc Peeters, Francesco Passiglia, Marta Román and Silvestre Vicent and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Ignacio Gil‐Bazo

101 papers receiving 2.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ignacio Gil‐Bazo Spain	31	1.2k	1.1k	1.0k	805	244	103	2.6k
Hiroaki Asano Japan	28	1.3k 1.0×	1.1k 1.0×	1.4k 1.3×	842 1.0×	146 0.6×	82	2.8k
Denis L. Jardim Brazil	21	625 0.5×	1.1k 0.9×	671 0.6×	619 0.8×	310 1.3×	63	2.0k
Wing‐Kai Chan Taiwan	22	1.4k 1.1×	1.4k 1.2×	1.2k 1.2×	828 1.0×	204 0.8×	57	3.2k
Hideharu Kimura Japan	26	825 0.7×	1.4k 1.2×	1.5k 1.5×	742 0.9×	133 0.5×	113	2.6k
Helena Linardou Greece	27	899 0.7×	1.8k 1.6×	1.2k 1.2×	653 0.8×	123 0.5×	87	2.8k
Kazunori Tsukuda Japan	34	2.1k 1.7×	1.5k 1.4×	1.5k 1.4×	1.0k 1.3×	155 0.6×	121	3.7k
Harold Keer United States	21	1.3k 1.1×	627 0.6×	1.2k 1.2×	610 0.8×	169 0.7×	75	2.6k
Sami Diab United States	27	812 0.7×	1.8k 1.5×	805 0.8×	1.0k 1.3×	202 0.8×	74	2.8k
Enric Carcereny Spain	26	856 0.7×	1.9k 1.6×	1.6k 1.5×	515 0.6×	338 1.4×	183	2.9k
Maria Giovanna Dal Bello Italy	27	636 0.5×	1.3k 1.1×	861 0.8×	509 0.6×	332 1.4×	86	2.1k

Countries citing papers authored by Ignacio Gil‐Bazo

Since Specialization

Citations

This map shows the geographic impact of Ignacio Gil‐Bazo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ignacio Gil‐Bazo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ignacio Gil‐Bazo more than expected).

Fields of papers citing papers by Ignacio Gil‐Bazo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ignacio Gil‐Bazo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ignacio Gil‐Bazo. The network helps show where Ignacio Gil‐Bazo may publish in the future.

Co-authorship network of co-authors of Ignacio Gil‐Bazo

This figure shows the co-authorship network connecting the top 25 collaborators of Ignacio Gil‐Bazo. A scholar is included among the top collaborators of Ignacio Gil‐Bazo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ignacio Gil‐Bazo. Ignacio Gil‐Bazo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gregorc, Vanesa, María González‐Cao, Stefania Salvagni, et al.. (2024). KROCUS: A phase II study investigating the efficacy and safety of fulzerasib (GFH925) in combination with cetuximab in patients with previously untreated advanced KRAS G12C mutated NSCLC.. Journal of Clinical Oncology. 42(17_suppl). LBA8511–LBA8511. 14 indexed citations

Aerts, Joachim G.J.V., Luis Paz‐Ares, Carole Hélissey, et al.. (2024). Acasunlimab (DuoBody-PD-L1x4-1BB) alone or in combination with pembrolizumab (pembro) in patients (pts) with previously treated metastatic non-small cell lung cancer (mNSCLC): Initial results of a randomized, open-label, phase 2 trial.. Journal of Clinical Oncology. 42(16_suppl). 2533–2533. 6 indexed citations

Vilalta, A., et al.. (2024). Liquid biopsy for monitoring minimal residual disease in localized and locally-advanced non-small cell lung cancer after radical-intent treatment. SHILAP Revista de lepidopterología. 4. 100145–100145. 2 indexed citations

Baraibar, Iosune, Laura Mezquita, Ignacio Gil‐Bazo, & David Planchard. (2020). Novel drugs targeting EGFR and HER2 exon 20 mutations in metastatic NSCLC. Critical Reviews in Oncology/Hematology. 148. 102906–102906. 48 indexed citations

Serrano, María José, M. Carmen Garrido-Navas, Juan J. Díaz‐Mochón, et al.. (2020). Precision Prevention and Cancer Interception: The New Challenges of Liquid Biopsy. Cancer Discovery. 10(11). 1635–1644. 53 indexed citations

Alegre, Estíbaliz, Ana Patiño‐García, Roser Ferrer, et al.. (2020). Performance comparison of two next-generation sequencing panels to detect actionable mutations in cell-free DNA in cancer patients. Clinical Chemistry and Laboratory Medicine (CCLM). 58(8). 1341–1348. 6 indexed citations

Alegre, Estíbaliz, Gorka Alkorta‐Aranburu, Ana Patiño‐García, et al.. (2019). The Dynamic Use of EGFR Mutation Analysis in Cell-Free DNA as a Follow-Up Biomarker during Different Treatment Lines in Non-Small-Cell Lung Cancer Patients. Disease Markers. 2019. 1–7. 11 indexed citations

Jang, Jae–Hwi, Ingrid De Meester, Stephan Arni, et al.. (2019). The CD26/DPP4-inhibitor vildagliptin suppresses lung cancer growth via macrophage-mediated NK cell activity. Carcinogenesis. 40(2). 324–334. 37 indexed citations

Reclusa, Pablo, Jean‐François Laes, Umberto Malapelle, et al.. (2018). EML4-ALK translocation identification in RNA exosomal cargo (ExoALK) in NSCLC patients: a novel role for liquid biopsy. Translational Cancer Research. 8(1). 7 indexed citations

10.

Martínez‐Terroba, Elena, Carmen Behrens, Jackeline Agorreta, et al.. (2018). 5 protein-based signature for resectable lung squamous cell carcinoma improves the prognostic performance of the TNM staging. Thorax. 74(4). 371–379. 9 indexed citations

11.

Rodríguez-Ruiz, María E., José Luis Perez‐Gracia, Inmaculada Rodríguez, et al.. (2018). Combined immunotherapy encompassing intratumoral poly-ICLC, dendritic-cell vaccination and radiotherapy in advanced cancer patients. Annals of Oncology. 29(5). 1312–1319. 114 indexed citations

12.

Alegre, Estíbaliz, Juan P. Fusco, Patricia Restituto, et al.. (2016). Total and mutated EGFR quantification in cell-free DNA from non-small cell lung cancer patients detects tumor heterogeneity and presents prognostic value. Tumor Biology. 37(10). 13687–13694. 34 indexed citations

13.

Mejías, Luis D., J. Espinós, P. Martin Romano, et al.. (2016). Impact of CD8 stromal lymphocytes in BC patients with the addition of autologous dendritic CELL vaccination to neoadjuvant chemotherapy.. Journal of Clinical Oncology. 34(15_suppl). 1081–1081. 2 indexed citations

14.

Cambeiro, Mauricio, Marta Moreno, Leire Arbea, et al.. (2016). Dose escalation with external beam radiation therapy and high-dose-rate brachytherapy combined with long-term androgen deprivation therapy in high and very high risk prostate cancer: Comparison of two consecutive high-dose-rate schemes. Brachytherapy. 15(2). 127–135. 20 indexed citations

15.

Bronte, Giuseppe, Christian Rolfo, Francesco Passiglia, et al.. (2015). What can platinum offer yet in the treatment of PS2 NSCLC patients? A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology. 95(3). 306–317. 20 indexed citations

16.

Redrado, Miriam, et al.. (2013). Spatial-temporal protein expression of inhibitor of differentiation-1 (Id1) during fetal embryogenesis and in different mouse and human cancer types.. PubMed. 28(8). 1029–40. 2 indexed citations

17.

Gil‐Bazo, Ignacio, et al.. (2012). Safety and Efficacy of Maintenance Therapy With a Nonspecific Cytochrome P17 Inhibitor (CYP17i) After Response/Stabilization to Docetaxel in Metastatic Castration-Resistant Prostate Cancer. Clinical Genitourinary Cancer. 11(2). 78–84. 2 indexed citations

18.

Ponz‐Sarvisé, Mariano, Paul Nguewa, Jackeline Agorreta, et al.. (2011). Inhibitor of Differentiation-1 as a Novel Prognostic Factor in NSCLC Patients with Adenocarcinoma Histology and Its Potential Contribution to Therapy Resistance. Clinical Cancer Research. 17(12). 4155–4166. 40 indexed citations

19.

Bosch‐Barrera, Joaquim, et al.. (2009). Toxic Epidermal Necrolysis Related to Pemetrexed and Carboplatin with Vitamin B12 and Folic Acid Supplementation for Advanced Non-Small Cell Lung Cancer. Onkologie. 32(10). 580–584. 20 indexed citations

20.

Gil‐Bazo, Ignacio. (2005). Role of von Willebrand factor levels in the prognosis of stage IV colorectal cancer: Do we have enough evidence?. World Journal of Gastroenterology. 11(38). 6072–6072. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact